Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Imfinzi EU Bladder Cancer Filing On Back Burner As AZ Focuses On Lung

Executive Summary

The CHMP decided against an accelerated review of Imfinzi in both bladder and lung cancer but unlike in the case of NSCLC, AstraZeneca has not filed for the former indication.


Related Content

PD-1 Earnings Roundup: Buckle Up For A Bumpy Ride
AZ Confident New Cancer Drugs Can Drive Return To Sales Growth
Roche's Atezolizumab Gets CDF Place For Bladder Cancer
US Filing For AZ’s Imfinzi In Stage III Lung Cancer
And Then There Were Five: Roche's Tecentriq Joins Europe I-O Race
AstraZeneca's Imfinzi Debuts In Bladder Cancer With Combo Coming Soon


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts